

Table SI. List of biopsies included in this study with patient clinicopathologic parameters and IHC staining scores for ER β and TLR4.

Case No.	Sex	Age at time of surgery (in years)	Tumor stage UICC	Tumor stage TNM	Lymph node metastasis ratio	IHC score of ER β		IHC score of TLR4	
						Primary tumor	Lymph node metastasis	Primary tumor	Lymph node metastasis
01	Female	48	III A	pT2aN2	11/13	++	++	+	-
02	Male	64	III A	pT2aN2	11/26	+	+++	++	++
03	Male	66	III A	pT2bN2	5/21	++	+++	-	++
04	Male	21	III A	pT2bN2	6/26	++	++	+	+++
05	Male	63	III A	pT2bN2	4/16	++	++	++	+++
06	Male	57	III A	pT2aN2	7/16	+	+++	+++	+++
07	Male	46	III A	pT2aN2	5/27	+++	+++	-	+++
08	Female	58	III B	pT3N3	4/14	+	+++	+++	+++
09	Male	52	III A	pT2aN2	5/18	++	++	+	+++
10	Male	38	III B	pT4N2	4/16	++	++	++	+++
11	Male	60	II B	pT2bN1	2/40	+	+++	+	++
12	Male	58	III A	pT3N2	11/18	+++	+++	+++	+++
13	Male	53	III B	pT2bN3	14/20	++	+++	-	+++
14	Female	57	III B	pT1bN3	9/12	+++	+++	++	+++
15	Male	42	III A	pT2aN2	14/32	+++	+++	+++	+++
16	Male	72	III A	pT2aN2	7/11	++	+++	+	+++
17	Male	64	II B	pT2aN1	1/10	++	++	+	+++
18	Male	61	III A	pT2bN2	2/10	+++	+++	++	+++
19	Male	65	III B	pT4N2	1/32	+++	+++	+	+++
20	Male	66	III A	pT2bN2	4/8	+++	++	++	+++
21	Male	67	II B	pT2aN1	2/14	++	+++	+++	+++
22	Male	53	III A	pT2aN2	11/23	+++	+++	++	+++
23	Male	59	III A	pT2aN2	16/31	++	+++	-	+++
24	Male	45	III B	pT2aN3	8/11	+	+++	+	+++
25	Male	60	III A	pT3N2	9/35	+++	++	+	+++
26	Male	59	III A	pT2aN2	7/20	++	+++	++	+++
27	Male	47	III A	pT2aN2	12/18	++	+++	-	+
28	Male	69	III A	pT2bN2	2/37	+	+++	+++	+++
29	Male	57	III A	pT3N1	1/11	+	+++	-	+++
30	Male	60	III A	pT2aN2	5/11	++	+++	+	++

IHC, immunohistochemical; ER β , estrogen receptor β ; TLR4, Toll-like receptor 4; UICC, Union for International Cancer Control; TNM, Tumor-Node-Metastasis. To note: a score of 1-16 was obtained by multiplying the staining intensity and proportion of positive cells: (-), ≤ 4 ; (+), >4 and $\leq$; (++) , >8 and ≤ 12 ; and (+++) , >12 and ≤ 16 .